Publicaciones en colaboración con investigadores/as de University of Paris-Saclay (8)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2023

  1. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 10, pp. 664-677

  2. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

2022

  1. A catalog of numerical centrosome defects in epithelial ovarian cancers

    EMBO Molecular Medicine, Vol. 14, Núm. 9

2020

  1. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654

2019

  1. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer

    European Journal of Cancer, Vol. 117, pp. 60-68

  2. Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1852-1859

2017

  1. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24